Surgery

Spirair Receives FDA Clearance for SeptAlign, the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation

Retrieved on: 
Monday, April 8, 2024
General Health, FDA, Surgery, Medical Devices, Health, NSD, Patient, NSR, St Luke's, NAO, ASC, Cartilage, Nose, FACS, Septum, University Health Network, Otorhinolaryngology, Physician, Luke the Evangelist, Food, IRB

This comes on the heels of FDA clearance of the SeptAlign bioabsorbable Implant in August 2023 and represents the final step in completing the FDA clearance process for the SeptAlign System.

Key Points: 
  • This comes on the heels of FDA clearance of the SeptAlign bioabsorbable Implant in August 2023 and represents the final step in completing the FDA clearance process for the SeptAlign System.
  • "Septal deviation is one of the primary contributors to nasal airway obstruction.
  • Physicians can't move septal cartilage with medicines so mechanical correction through surgery has been the best choice for many patients.
  • Following the clearance of the SeptAlign system, Spirair plans to begin a Series B fundraising round and start commercialization.

MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.

Retrieved on: 
Monday, April 8, 2024
Technology, Medical Devices, Surgery, Hospitals, FDA, Health Technology, Hardware, Robotics, Health, Oncology, Freedom, Surgeon, Classification, Lymphedema, Filtration, Physician, Patient, Hospital, European, Platform supply vessel, Tremor, Blood, Wrist, Hand, Microsurgery, Food, Medicine, Dentistry

The FDA authorization makes the Symani Surgical System the only commercially available platform in the U.S. for reconstructive microsurgery.

Key Points: 
  • The FDA authorization makes the Symani Surgical System the only commercially available platform in the U.S. for reconstructive microsurgery.
  • “With the authorization from the FDA, our technology will expand its reach to pioneering hospitals in the U.S.
  • The Symani Surgical System provides advanced solutions for a range of open surgeries, including post-mastectomy breast cancer reconstruction, extremity reconstruction using free tissue transfer, and lymphatic system repair.
  • MMI plans to immediately launch the technology in the U.S.
    To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com .

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE

"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."

Key Points: 
  • "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
  • An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
  • The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
  • Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

Alcon Publishes Agenda for 2024 Annual General Meeting

Retrieved on: 
Sunday, April 7, 2024
Optical, Health, Surgery, Medical Devices, AGM, Executive Committee, Bank statement, Commerce, Annual general meeting, CHF, Hearing, Report

Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024.

Key Points: 
  • Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024.
  • The company looks forward to hearing directly from its shareholders at this open format meeting.
  • The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters.
  • Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2023
    3.

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

Retrieved on: 
Sunday, April 7, 2024
Technology, Medical Devices, Surgery, Health Technology, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Diagnosis, TTE, Machine learning, Cardiovascular disease, Coronary artery disease, Pulmonary hypertension, Patient, Heart, Heart failure, American College, Data collection, FDA, CAD

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.

Key Points: 
  • The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.
  • Timely identification of left ventricular dysfunction plays a pivotal role in effective heart failure management, however, measuring elevated LVEDP currently relies on invasive left heart catheterization.
  • Sc.D., Executive Vice President and Chief Scientific Officer, CorVista Health.
  • “We believe the CorVista System can uniquely and effectively address these important unmet needs for people living with cardiovascular disease, especially in rural and underserved populations.”

Tampa General Hospital Honored as a Leading Industry Innovator by Modern Healthcare

Retrieved on: 
Tuesday, April 9, 2024
Research, Tampa General Hospital, Culture, Sepsis, Organization, Biotechnology, Growth, Rehabilitation hospital, Environment, Intelligence, Partnership, Education, TGH, Patient, News, Neuroscience, Student, GE HealthCare, City, Investment, Infection, Patient safety, Modern Healthcare, Workplace, Surgery, Nursing

TAMPA, Fla., April 9, 2024 /PRNewswire/ -- Tampa General Hospital (TGH) is one of 10 organizations nationwide recognized in Modern Healthcare's Innovators Class of 2024. This award program highlights leaders and organizations, selected by Modern Healthcare's editorial team, who are driving innovation that improves care, achieves measurable results and advances the clinical and financial goals of the organization.

Key Points: 
  • TAMPA, Fla., April 9, 2024 /PRNewswire/ -- Tampa General Hospital (TGH) is one of 10 organizations nationwide recognized in Modern Healthcare's Innovators Class of 2024.
  • "At Tampa General, we're dedicated to driving innovation by leveraging the latest technologies, forging dynamic partnerships and implementing strategic initiatives that enhance patient outcomes, accessibility and affordability," said John Couris, president and CEO of Tampa General.
  • Modern Healthcare is a leading source of healthcare business news.
  • Tampa General and the full Innovators Class of 2024 are profiled in the April 8 print edition of the magazine and online here .

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

Retrieved on: 
Wednesday, March 20, 2024
Cell adhesion, Ulcer, Wound, Partnership, Patient, Trauma, Surgeon, Wound healing, Collagen, Surgery

Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.

Key Points: 
  • Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We are excited to announce the formation of this partnership with Regenity and believe it is an important step toward achieving our long-term growth plan.
  • As we have stated, one of our strategic priorities is to augment our best-in-class placental-derived product portfolio with xenografts and/or synthetic skin substitutes in order to meet the needs of a greater number of customers, domestically and abroad.
  • The collagen in this product serves as a dressing that allows for cell adhesion and migration into the wound site and supports wound healing.
  • “Additionally, we look forward to partnering with Regenity and leveraging their expertise to bring other products in our pipeline to market in the future.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
Wednesday, March 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”

Global Medical Aesthetics Market, 2023-2035: Dominance of Minimally Invasive Procedures - North America Leads, Asia-Pacific Shows Promise - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Other Consumer, Medical Devices, Surgery, Women, LGBTQ+, Men, Consumer, Health, Cosmetics, Retail, Migraine, Type, Medical tourism, Elective surgery, COVID-19, Bariatric surgery, Hospital, Dermatology, IPL, Ageing, Breast, Cellulite, Safety, Market, Physician, FACE, Practitioner

The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.

Key Points: 
  • The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.
  • Presently, more than 200 medical aesthetics companies are engaged in offering various products and devices to fulfill aesthetic requirements of clients.
  • Additionally, medical aesthetic companies offer all types of invasive, non invasive and minimally invasive solutions to address the requirements of all end users, such as hospitals, medical aesthetic clinic and individuals in home care settings.
  • North America leads the medical aesthetics market, driven by advanced solutions, established companies, and high demand for cosmetic procedures.